BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10878820)

  • 1. VHL takes HIF's breath away.
    Krek W
    Nat Cell Biol; 2000 Jul; 2(7):E121-3. PubMed ID: 10878820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
    Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K; Makino Y; Pereira T; Poellinger L
    EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
    J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
    Jaakkola P; Mole DR; Tian YM; Wilson MI; Gielbert J; Gaskell SJ; von Kriegsheim A; Hebestreit HF; Mukherji M; Schofield CJ; Maxwell PH; Pugh CW; Ratcliffe PJ
    Science; 2001 Apr; 292(5516):468-72. PubMed ID: 11292861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer. Many vessels, faulty gene.
    Kaelin WG
    Nature; 1999 May; 399(6733):203-4. PubMed ID: 10353237
    [No Abstract]   [Full Text] [Related]  

  • 12. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Hippel-Lindau tumor suppressor protein.
    Ivan M; Kaelin WG
    Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
    Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
    IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
    Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
    J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW; Ratcliffe PJ
    Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Hippel-Lindau tumor suppressor: not only HIF's executioner.
    Czyzyk-Krzeska MF; Meller J
    Trends Mol Med; 2004 Apr; 10(4):146-9. PubMed ID: 15162797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
    Kamura T; Sato S; Iwai K; Czyzyk-Krzeska M; Conaway RC; Conaway JW
    Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10430-5. PubMed ID: 10973499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.
    Masson N; Willam C; Maxwell PH; Pugh CW; Ratcliffe PJ
    EMBO J; 2001 Sep; 20(18):5197-206. PubMed ID: 11566883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.